World Class Bodybuilding   Forum

BulkSupplements Egg Whites International A1Supplements.com i-Supplements HideMyAss
Go Back   World Class Bodybuilding Forum > Anabolic Steroid Discussion > SARMs > SARMS RSS Feeds

Shoutbox
Loading...


SARMS RSS Feeds Selective Androgen Receptor Modulators




Reply
 
Thread Tools Search this Thread Display Modes
  #1  
Old 05-04-2016, 07:01 AM
Bodybuilding Peptides's Avatar
Bodybuilding Peptides Bodybuilding Peptides Is Off Line
Sponsor

 
Join Date: Feb 2009
Posts: 5,110
Thanks: 1
Thanked 32 Times in 23 Posts
Rep Power: 177
Bodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to beholdBodybuilding Peptides is a splendid one to behold
rss Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm,

Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).

Curr Oncol Rep. 2016 Jun;18(6):37

Authors: Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT

Abstract
Muscle wasting in cancer is a common and often occult condition that can occur prior to overt signs of weight loss and before a clinical diagnosis of cachexia can be made. Muscle wasting in cancer is an important and independent predictor of progressive functional impairment, decreased quality of life, and increased mortality. Although several therapeutic agents are currently in development for the treatment of muscle wasting or cachexia in cancer, the majority of these agents do not directly inhibit muscle loss. Selective androgen receptor modulators (SARMs) have the potential to increase lean body mass (LBM) and hence muscle mass, without the untoward side effects seen with traditional anabolic agents. Enobosarm, a nonsteroidal SARM, is an agent in clinical development for prevention and treatment of muscle wasting in patients with cancer (POWER 1 and 2 trials). The POWER trials are two identically designed randomized, double-blind, placebo-controlled, multicenter, and multinational phase 3 trials to assess the efficacy of enobosarm for the prevention and treatment of muscle wasting in subjects initiating first-line chemotherapy for non-small-cell lung cancer (NSCLC). To assess enobosarm's effect on both prevention and treatment of muscle wasting, no minimum weight loss is required. These pivotal trials have pioneered the methodological and regulatory fields exploring a therapeutic agent for cancer-associated muscle wasting, a process hereby described. In each POWER trial, subjects will receive placebo (n = 150) or enobosarm 3.mg (n = 150) orally once daily for 147.days. Physical function, assessed as stair climb power (SCP), and LBM, assessed by dual-energy X-ray absorptiometry (DXA), are the co-primary efficacy endpoints in both trials assessed at day 84. Based on extensive feedback from the US Food and Drug Administration (FDA), the co-primary endpoints will be analyzed as a responder analysis. To be considered a physical function responder, a subject must have >=10.% improvement in physical function compared to baseline. To meet the definition of response on LBM, a subject must have demonstrated no loss of LBM compared with baseline. Secondary endpoints include durability of response assessed at day 147 in those responding at day 84. A combined overall survival analysis for both studies is considered a key secondary safety endpoint. The POWER trials design was established with extensive clinical input and collaboration with regulatory agencies. The efficacy endpoints are a result of this feedback and discussion of the threshold for clinical benefit in patients at risk for muscle wasting. Full results from these studies will soon be published and will further guide the development of future anabolic trials. Clinical Trial ID: NCT01355484. https://clinicaltrials.gov/ct2/show/NCT01355484 , NCT01355497. https://clinicaltrials.gov/ct2/show/...g300505&rank=1 .


PMID: 27138015 [PubMed - as supplied by publisher]



Read more on this here
This is an automated post
__________________
W C B B Affiliates

PowderCity.com <---Best Selling Products
BulkSupplements.com <---Save Money, Buy in BULK
IslandSupplements.com <--- Latest Sale Items
I-supplements.com <--- Vip Special Offers
A1Supplements.com <----Clearance Supplements
HideMyAss Security Proxy<---- Protect your online activity
Home Chemistry Conversions <-- home chemistry needs
Help WCBB by using our AMAZON.com link use for any amazon purchase.
Egg Whites International <---100% Bio-Available Egg White Protein
Liquid egg whites recipes ,-- protein shakes, smoothies, full delicious meals etc.
Egg White Fitness Website <-- Site all about Egg Whites
WorldClassBodyBuilding Teeshirts <-- get your WCBB t-shirts here, first design to latest
Reply With Quote
Get your liquid egg whites here at EGG WHITES INTERNATIONAL

Reply

Bookmarks


Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -4. The time now is 10:56 PM.



Copyright ©2000 - 2017, Jelsoft Enterprises Ltd.
follow worldclassbodybuilding at facebook follow worldclassbodybuilding at pinterest follow worldclassbodybuilding at twitter